Physician profile
Shawn E Mccandless
NPI 1285650150
$32,686.81
in general payments reported to CMS, 2019-2025
10 companies · $3,617 in 2025
The $3,617 reported for 2025 was more than what 75% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $10K · 2021: $5,233 · 2022: $7,906 · 2023: $5,451 · 2024: $90.77 · 2025: $3,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,916 · Consulting Fee: $2,492 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,916.00 |
| Consulting Fee | $2,491.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Food and Beverage | $251.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $27,899.93 | 2019-2023 | Ravicti |
| Acadia Pharmaceuticals INC | $3,500.00 | 2025 | Acp-101 |
| Rhythm Pharmaceuticals, INC. | $516.00 | 2023 | Imcivree |
| Biomarin Pharmaceutical INC. | $513.81 | 2019-2023 | |
| Orchard Therapeutics North America | $116.85 | 2025 | Lenmeldy |
| Amgen INC. | $90.77 | 2024 | Ravicti |
| Ultragenyx Pharmaceutical INC. | $30.00 | 2020 | |
| Travere Therapeutics, INC. | $19.45 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Mccandless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.